New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:25 EDTCDXC, CDXC, SNTI, SNTI, ETAK, ETAK, TWER, TWER, ANDA, ANDA, SFE, SFE, ABMD, ABMD, TALN, TALN, AXGN, AXGN, PED, PEDNoble Financial Capital Markets to host a conference
10th Annual Equity Conference is being held in Sandpiper Bay, Florida on January 19-22 with webcasted company presentations to begin on January 22 at 8:30 am; not all company presentations may be webcasted. Webcast Link
News For CDXC;AXGN;TALN;ABMD;SFE;ANDA;TWER;ETAK;SNTI;PED From The Last 14 Days
Check below for free stories on CDXC;AXGN;TALN;ABMD;SFE;ANDA;TWER;ETAK;SNTI;PED the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:05 EDTABMDAbiomed acquires exclusive license for Opsens' optical sensor technology
Abiomed announced its acquisition of an exclusive license from collaboration partner Opsens. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab. This licensing agreement, which secures Abiomed's rights to the technology and gives Abiomed the right to manufacture the sensors, is a continuation of an initial collaboration, entered into between Opsens and Abiomed in 2010.
April 10, 2014
07:34 EDTABMDAbiomed shares attractive following recent weakness, says Stephens
Stephens believes Abiomed shares are attractively valued following their recent weakness given the stock's valuation relative to peers. The firm says Abiomed remains one of its top ideas and reiterates its Overweight rating and $34 price target on the stock.
April 8, 2014
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use